Boehringer Ingelheim’s blockbuster diabetes drug goes off patent today—Will it lower treatment costs in India?
- Posted on March 11, 2025
- By Financial Express
- 4 Views
Boehringer Ingelheim’s blockbuster diabetes drug goes off patent today—Will it lower treatment costs in India?
Empagliflozin is a SGLT-2 inhibitor and it has shown to significantly reduce the progression of kidney disease and heart failure.
